Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialDavid J. Kuter, Janet L. Nichol, Howard A. Liebman et al.|The Lancet|2008Cited by 862
Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trialsJames N. George, Martin R. Schipperus, Susan D. Mathias et al.|British Journal of Haematology|2008Cited by 146
Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.David J. Kuter, Janet L. Nichol, James B. Bussel et al.|Blood|2006Cited by 30
Long-Term Dosing of AMG 531 Is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura.James B. Bussel, Janet L. Nichol, David J. Kuter et al.|Blood|2005Cited by 23
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemiaArnon P. Kater, Mark‐David Levin, Marinus H. J. van Oers et al.|Haematologica|2018Cited by 13